3 Further information

3 Further information

3.1 NICE has published technology appraisal guidance on temozolomide for the treatment of recurrent malignant glioma (brain cancer) and carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma, and service guidance for improving outcomes for people with brain and other central nervous system tumours.

Information for patients

NICE has produced information on this procedure for patients and carers ('Understanding NICE guidance'). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.

  • National Institute for Health and Care Excellence (NICE)